Latest Biotech News

Gilead expanded its Tempus partnership, granting the drugmaker broader access to Tempus’s multimodal real-world cancer dataset library and its AI platform. Tempus said the multi-year collaboration...

Gilead agreed to pay Kymera Therapeutics $45 million to exercise an option on a preclinical anticancer molecular glue degrader, adding another oncology asset to a pipeline built through...

Researchers from The Hebrew University of Jerusalem reported that blocking neuronal nitric oxide synthase (nNOS) suppresses neuroblastoma growth by disrupting an AKT–TSC–mTOR signaling cascade....

Insilico-accelerated drug discovery aside, one clinically oriented delivery theme that emerged in the dataset is long-term intranasal oxytocin work aimed at stabilizing exposure beyond short-lived...

A preclinical report described engineered dendritic cells that prevent cardiac remodeling, targeting the fibrotic processes that drive progression to heart failure. The approach is positioned...

Grail partnered with Epic to integrate access to the Galleri multi-cancer early detection test directly within Epic electronic health record platforms. Under the agreement, clinicians can order...

Sidewinder Therapeutics emerged from stealth with an oversubscribed $137 million Series B, backed by investors including OrbiMed and Novartis’ venture arm. The San Diego biotech is developing...

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion in cash, a deal designed to scale a marketed therapy for Prader-Willi syndrome. The transaction includes Soleno’s...

Roche has entered the antibody-targeted protein degrader space by expanding its C4 Therapeutics collaboration, committing $20 million upfront for two oncology targets and more than $1 billion in...

Sidewinder Therapeutics emerged from stealth with an oversubscribed $137 million Series B, pitching a bispecific ADC approach designed to improve tumor targeting while reducing toxicities. The San...

Gilead agreed to acquire ADC specialist Tubulis in a deal valued at up to $5 billion, following multiple large transactions since late February. The acquisition includes $3.15 billion upfront plus...

Avalyn Pharma filed for an IPO to fund late-stage development of inhaled reformulations of approved pulmonary fibrosis drugs. The Cambridge-based company plans to move AP01 (inhaled pirfenidone)...

Biogen strengthened the clinical case for BDCA2 as a therapeutic target in cutaneous lupus erythematosus after a second Phase II success for litifilimab (an investigational anti-BDCA2 therapy)....

Dynamic42 and EPO (Experimental Pharmacology and Oncology) announced a collaboration to bring organ-on-chip platforms earlier into preclinical glioblastoma workflows. The partners will pair...

23andMe reported new genetic findings tied to outcomes and side effects from GLP-1 receptor agonist therapies. In a Nature study, investigators analyzed 27,885 research-consented participants and...

Grail expanded access to its Galleri multi-cancer early detection test by partnering with Epic to integrate test ordering directly into Epic’s electronic health record workflows. Clinicians using...

Neurocrine agreed to acquire Soleno Therapeutics for $2.9 billion, expanding its commercial portfolio in endocrinology and rare disease. The deal includes cash consideration of $53.00 per share,...

Amplia Therapeutics halted enrollment in its Phase II Amplicity trial for advanced pancreatic cancer after three dose-limiting toxicities tied to the modified FOLFIRINOX regimen combined with...

Gilead Sciences has agreed to acquire German ADC specialist Tubulis for up to $5 billion, seeking to expand its antibody-drug conjugate platform with new linker and payload technologies. The deal...

Jeito Capital, a prominent European biopharma investor, closed its second independent fund at more than €1 billion (about $1.2 billion), topping its target and raising the firm’s AUM to €1.6...